Metsera (MTSR) Stock Price, News & Analysis

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Key Stats

• Today's Range: $26.78 to $29.55
• 50-Day Range: $13.08 to $29.52
• 52-Week Range: $12.30 to $32.81
• Volume: 391,840 shs
• Average Volume: 866,695 shs
• Market Capitalization: $2.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.00
• Consensus Rating: Buy

MTSR Stock Analysis - Frequently Asked Questions

How have MTSR shares performed this year?

Metsera's stock was trading at $29.50 at the start of the year. Since then, MTSR stock has decreased by 6.8% and is now trading at $27.49.
View the best growth stocks for 2025 here.

How were Metsera's earnings last quarter?

Metsera, Inc. (NASDAQ:MTSR) issued its quarterly earnings data on Monday, May, 12th. The company reported ($1.03) EPS for the quarter.

When did Metsera IPO?

Metsera (MTSR) raised $275 million in an IPO on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $18.00 per share.

When does the company's lock-up period expire?

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Metsera's major shareholders?

Metsera's top institutional investors include Alphabet Inc. (4.72%), T. Rowe Price Investment Management Inc. (2.75%), Wellington Management Group LLP (2.29%) and Alpha Wave Global LP (2.27%).

How do I buy shares of Metsera?

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTSR
• Previous Symbol: NASDAQ:MTSR
• CIK: 2040807
• Web: N/A
• Phone: (212) 784-6595
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.00
• High Stock Price Target: $56.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +71.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 105,056,000
• Free Float: N/A
• Market Cap: $2.89 billion
• Optionable: N/A
• Beta: N/A